Payment overview · 2025
General Payments
$305.75
15 reported records · 6 companies
Healthcare provider profile · identity verified
Robert Eaker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SWEETWATER, TX · NPI 1679518104
Verified facts
What the public records show
CMS Open Payments records show Robert Eaker, M.D. received $305.75 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $181.37 | 59.3% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.76 | 13.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.10 | 9.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.25 | 8.3% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.56 | 5.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.71 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.75 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $94.59 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.07 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 197 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
197 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 89 |
| Losartan Potassium | Losartan Potassium | 318 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 70 |
| Lisinopril | Lisinopril | 259 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 53 |
| Gabapentin | Gabapentin | 227 | 49 |
| Potassium Chloride | Potassium Chloride | 223 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 50 |
| Farxiga | Dapagliflozin Propanediol | 197 | 37 |
| Simvastatin | Simvastatin | 183 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 26 |
| Eliquis | Apixaban | 172 | 27 |
| Tramadol Hcl | Tramadol Hcl | 170 | 34 |
| Metformin Hcl Er | Metformin Hcl | 169 | 49 |
| Furosemide | Furosemide | 157 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 32 |
| Donepezil Hcl | Donepezil Hcl | 153 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 34 |
| Sertraline Hcl | Sertraline Hcl | 153 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 145 | 25 |
| Trulicity | Dulaglutide | 143 | 19 |
| Metformin Hcl | Metformin Hcl | 132 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 32 |
| Alendronate Sodium | Alendronate Sodium | 129 | 43 |
| Carvedilol | Carvedilol | 118 | 25 |
| Trazodone Hcl | Trazodone Hcl | 118 | 17 |
| Pregabalin | Pregabalin | 117 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 24 |
| Alprazolam | Alprazolam | 113 | 19 |
| Ozempic | Semaglutide | 108 | 19 |
| Mounjaro | Tirzepatide | 107 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 25 |
| Jardiance | Empagliflozin | 87 | 11 |
| Clonazepam | Clonazepam | 85 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 84 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 23 |
| Allopurinol | Allopurinol | 79 | 17 |
| Finasteride | Finasteride | 79 | 16 |
| Meloxicam | Meloxicam | 78 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 26 |
| Omeprazole | Omeprazole | 73 | 20 |
| Montelukast Sodium | Montelukast Sodium | 71 | 18 |
| Celecoxib | Celecoxib | 70 | 16 |
| Memantine Hcl | Memantine Hcl | 69 | 14 |
| Atenolol | Atenolol | 66 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 11 |
| Famotidine | Famotidine | 63 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 42 |
| Ezetimibe | Ezetimibe | 60 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 15 |
| Ondansetron Odt | Ondansetron | 58 | 18 |
| Mirtazapine | Mirtazapine | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 39 |
| Prednisone | Prednisone | 49 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 11 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Temazepam | Temazepam | 48 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Fluconazole | Fluconazole | 36 | 13 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 30 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 11 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 22 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Viberzi | Eluxadoline | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Orencia Clickject | Abatacept | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vardenafil Hcl | Vardenafil Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.75 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, FARXIGA, Ozempic, Qelbree, Rybelsus, VRAYLAR, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error